×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VRDN – viridian therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VRDN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/10
07:24 am
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/10
07:00 am
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/27
07:27 am
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Low
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/27
07:00 am
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
2/6
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/8
07:00 am
vrdn
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
High
Report
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
1/7
08:04 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
2/27/2025
07:00 am
VRDN
viridian therapeutics, inc.
BEAT
Report
8.0%
viridian therapeutics, inc.
2/27/2025
07:00 am
VRDN
viridian therapeutics, inc.
BEAT
Report
-0.7%
viridian therapeutics, inc.
2/27/2025
07:00 am
VRDN
viridian therapeutics, inc.
BEAT
Report
-0.7%
viridian therapeutics, inc.
2/27/2025
07:00 am
VRDN
viridian therapeutics, inc.
BEAT
Report
-0.7%
viridian therapeutics, inc.
Date
Time
Symbol
Headline
Impact
3/12
04:36 pm
vrdn
Form 4 Viridian Therapeutics, For: Mar 10 Filed by: Tripuraneni Radhika
Medium
Report
Form 4 Viridian Therapeutics, For: Mar 10 Filed by: Tripuraneni Radhika
3/12
04:27 pm
vrdn
Form 3 Viridian Therapeutics, For: Mar 10 Filed by: Tripuraneni Radhika
Medium
Report
Form 3 Viridian Therapeutics, For: Mar 10 Filed by: Tripuraneni Radhika
3/12
04:20 pm
vrdn
Form 4 Viridian Therapeutics, For: Mar 10 Filed by: CAIN CHRISTOPHER W.
Medium
Report
Form 4 Viridian Therapeutics, For: Mar 10 Filed by: CAIN CHRISTOPHER W.
3/12
04:17 pm
vrdn
Form 3 Viridian Therapeutics, For: Mar 10 Filed by: CAIN CHRISTOPHER W.
Medium
Report
Form 3 Viridian Therapeutics, For: Mar 10 Filed by: CAIN CHRISTOPHER W.
3/10
04:12 pm
vrdn
Form 8-K Viridian Therapeutics, For: Mar 05
Medium
Report
Form 8-K Viridian Therapeutics, For: Mar 05
3/4
09:17 pm
vrdn
Form 4 Viridian Therapeutics, For: Mar 03 Filed by: Tousignant Jennifer
Low
Report
Form 4 Viridian Therapeutics, For: Mar 03 Filed by: Tousignant Jennifer
3/4
09:14 pm
vrdn
Form 4 Viridian Therapeutics, For: Mar 03 Filed by: Mahoney Stephen F.
Low
Report
Form 4 Viridian Therapeutics, For: Mar 03 Filed by: Mahoney Stephen F.
3/4
09:13 pm
vrdn
Form 4 Viridian Therapeutics, For: Mar 03 Filed by: Harmon Seth
Low
Report
Form 4 Viridian Therapeutics, For: Mar 03 Filed by: Harmon Seth
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: